CytoSorbents Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Core Insights - CytoSorbents Corporation reported a transitional year in 2025, achieving a revenue of $37.1 million, a 4% increase year-over-year, and a gross margin of 71% [3][4]. - The company is focused on achieving cash flow breakeven in the second half of 2026, supported by a strategic workforce and cost reduction program [2][26]. Financial Performance - Full-year revenue for 2025 was $37.1 million, up from $35.6 million in 2024, with a gross margin improvement from 70% to 71% [4]. - The operating loss improved by 10% to $14.7 million in 2025 compared to $16.5 million in 2024, while the net loss decreased to $8.2 million or $0.13 per share from $20.7 million or $0.38 per share in 2024 [4][24]. - In Q4 2025, revenue was $9.2 million, a 1% increase year-over-year, with a gross margin of 74% compared to 70% in Q4 2024 [4][5]. Business Highlights - The company has made significant progress in sales performance, with a 13% increase in direct sales outside Germany and an 11.4% increase in distributor sales, which together accounted for approximately 68% of total sales [5]. - CytoSorbents surpassed 300,000 cumulative CytoSorb treatments globally by the end of 2025, indicating broad adoption of its therapy across over 70 countries [6]. - The company is actively engaging with the FDA regarding a new De Novo application for DrugSorb-ATR, which aims to reduce serious perioperative bleeding in patients treated with blood thinners [15][17]. Clinical Momentum - New clinical data supports the use of CytoSorb in critical care, particularly for sepsis and septic shock, with significant reductions in inflammatory markers and improved patient outcomes reported in various studies [7][9]. - A recent multinational survey indicated that over 75% of physicians use extracorporeal blood purification primarily for refractory septic shock, with CytoSorb being the most preferred modality [9]. Regulatory Updates - The FDA confirmed no safety concerns regarding DrugSorb-ATR but required additional information for the proposed label indication, leading to a decision to submit a new De Novo application [17][18]. - The company anticipates a regulatory decision within a typical 150-day review period following the new submission [18]. Strategic Initiatives - The company implemented a strategic workforce and cost reduction program in Q4 2025, reducing headcount by 10% to lower expenses and realign operational spending [25]. - CytoSorbents aims to leverage clinical evidence to educate users on effective treatment strategies, which is expected to support sustained growth across all sales channels [14].